Terug
35
46
Dagbereik
€ 2,97
€ 3,51
52-Weeksbereik
€ 2,97
€ 3,51
Volume
325
50D / 200D Gem.
€ 3,17
/
€ 3,19
Vorige Slotkoers
€ 2,97
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 2,4 | 0,3 |
| P/B | 0,1 | 2,9 |
| ROE % | 4,2 | 3,7 |
| Net Margin % | 3,0 | 3,8 |
| Rev Growth 5Y % | 4,9 | 10,0 |
| D/E | 0,2 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2028 |
€ 2,64
€ 2,59 – € 2,68
|
12 B | 1 |
| FY2027 |
€ 2,28
€ 2,24 – € 2,31
|
11 B | 1 |
| FY2026 |
€ 1,97
€ 1,94 – € 2,00
|
11 B | 1 |
Belangrijkste Punten
Revenue grew 4,94% annually over 5 years — modest growth
Earnings declined -32,93% over the past year
ROE of 4,23% is below average
Debt/Equity of 0,17 — conservative balance sheet
Generating 755,10M in free cash flow
P/E of 2,42 — trading at a low valuation
Groei
Revenue Growth (5Y)
4,94%
Revenue (1Y)-2,59%
Earnings (1Y)-32,93%
FCF Growth (3Y)-28,01%
Kwaliteit
Return on Equity
4,23%
ROIC7,14%
Net Margin3,04%
Op. Margin7,55%
Veiligheid
Debt / Equity
0,17
Current Ratio1,83
Interest Coverage3,99
Waardering
P/E Ratio
2,42
P/B Ratio0,11
EV/EBITDA1,49
Dividend Yield0,03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -2,59% | Revenue Growth (3Y) | 0,09% |
| Earnings Growth (1Y) | -32,93% | Earnings Growth (3Y) | -16,58% |
| Revenue Growth (5Y) | 4,94% | Earnings Growth (5Y) | -18,09% |
| Profitability | |||
| Revenue (TTM) | 11,00B | Net Income (TTM) | 334,00M |
| ROE | 4,23% | ROA | 2,23% |
| Gross Margin | 39,13% | Operating Margin | 7,55% |
| Net Margin | 3,04% | Free Cash Flow (TTM) | 755,10M |
| ROIC | 7,14% | FCF Growth (3Y) | -28,01% |
| Safety | |||
| Debt / Equity | 0,17 | Current Ratio | 1,83 |
| Interest Coverage | 3,99 | Dividend Yield | 0,03% |
| Valuation | |||
| P/E Ratio | 2,42 | P/B Ratio | 0,11 |
| P/S Ratio | 0,07 | PEG Ratio | -0,76 |
| EV/EBITDA | 1,49 | Dividend Yield | 0,03% |
| Market Cap | 807,58M | Enterprise Value | 1,24B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 11,00B | 11,29B | 10,98B | 9,98B | 9,07B |
| Net Income | 334,00M | 498,00M | 480,00M | 449,00M | 742,00M |
| EPS (Diluted) | 1,23 | 1,83 | 1,76 | 1,65 | 2,72 |
| Gross Profit | 4,30B | 4,91B | 4,74B | 4,21B | 4,21B |
| Operating Income | 831,00M | 893,00M | 884,00M | 691,00M | 1,08B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 14,98B | 16,28B | 15,44B | 16,17B | 14,61B |
| Total Liabilities | 7,52B | 7,94B | 7,86B | 8,54B | 7,73B |
| Shareholders' Equity | 7,46B | 8,34B | 7,58B | 7,62B | 6,89B |
| Total Debt | 1,27B | 5,42B | 5,49B | 6,31B | 5,45B |
| Cash & Equivalents | 836,00M | 892,00M | 923,00M | 949,00M | 757,00M |
| Current Assets | 4,32B | 4,85B | 4,42B | 5,03B | 4,17B |
| Current Liabilities | 2,37B | 4,60B | 4,40B | 4,62B | 6,49B |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#551 of 827
#161 of 709
Recente Activiteit
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026